Association between muscle mass and adverse events of chemotherapy for ovarian cancer
Abstract
Objetivo: identificar se existe associação entre a massa muscular e os eventos adversos do tratamento quimioterápico em mulheres com câncer de ovário. Métodos: coorte retrospectiva de 2014 a 2019, composta por 111 mulheres. Coletou-se dados sociodemográficos, da doença e do tratamento quimioterápico, eventos adversos e índice de massa corporal (IMC). A análise da composição corporal foi feita a partir da tomografia computadorizada realizada no diagnóstico e analisadas com auxílio do software Slice-O-matic V4.3 (Tomovision). Resultados: a idade das participantes variou de 21 a 88 anos. Antes de iniciar o tratamento, 14,4% apresentavam perda de peso, 53,9% eram eutróficas, 6,1% apresentavam baixo peso, que ao final do tratamento eram 31,3%. A composição corporal de massa muscular de 72,2% das mulheres estava na faixa de 21 a 30%. Os eventos adversos mais frequentes foram: náusea, vômito e fadiga muscular, que não apresentaram significância com a composição corporal, sendo esta observada apenas com a fadiga muscular após primeiro ciclo de quimioterapia. Conclusão: a diminuição da massa muscular se associou significativamente à fadiga muscular no início da quimioterapia, destacando a importância de monitorar a composição corporal para otimizar o manejo de mulheres com câncer de ovário.
Downloads
References
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. Doi: https://doi.org/10.3322/caac.21708.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. Doi: https://doi.org/10.3322/caac.21834.
Mendes FSB, Dolabela MF. Quimioterapia adjuvante para o tratamento do câncer de ovário e o cuidado farmacêutico: uma revisão integrativa. Res Soc Dev. 2021;10(16):e497101620638. Doi: http://dx.doi.org/10.33448/rsd-v10i16.20638.
Coleridge SL, Bryant A, Kehoe S, Morrison J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021;2(2):CD005343. Doi: https://doi.org/10.1002/14651858.CD005343.pub4.
Silva RF. Análise de determinantes sociais, clínicos e do sistema de saúde no não recebimento de cirurgia em câncer epitelial de ovário no Brasil [dissertação]. 2023. Disponível em: https://www.arca.fiocruz.br/handle/icict/62859.
Su S, Shao R, Sun M, Bai J, Jiang H, Zhang Y. Sarcopenia diagnosed by computed tomography predicts postoperative complications in advanced epithelial ovarian cancer. Aging Clin Exp Res. 2024;37(1):6. Doi: https://doi.org/10.1007/s40520-024-02901-9.
Imbimbo G, Pellegrini M, Scagnoli S, Pisegna S, Rizzo V, Gallicchio C, et al. Association between body composition parameters and treatment-related toxicities in patients with metastatic breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors. Clin Nutr. 2025;47:242-7. Doi: https://doi.org/10.1016/j.clnu.2025.02.031.
Prado CM, Baracos VE, Xiao J, Birdsell L, Stuyckens K, Park YC, et al. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab. 2014;39(6):693-8. Doi: https://doi.org/10.1139/apnm-2013-0403.
Qin N, Jiang G, Zhang X, Sun D, Liu M. The effect of nutrition intervention with oral nutritional supplements on ovarian cancer patients undergoing chemotherapy. Front Nutr. 2021;8:685967. Doi: https://doi.org/10.3389/fnut.2021.685967.
Drami I, Pring ET, Gould L, Malietzis G, Naghibi M, Athanasiou T, et al. Body composition and dose-limiting toxicity in colorectal cancer chemotherapy treatment: a systematic review of the literature. Clin Oncol (R Coll Radiol). 2021;33(12):e540-e52. Doi: https://doi.org/10.1016/j.clon.2021.05.011.
Shah S. Common terminology criteria for adverse events [Internet]. National Cancer Institute: USA; 2022. Disponível em: https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events.
Gandolfo AS, Delgado AF, Zamberlan P. Cálculo e classificação do índice de massa corpórea (IMC). In: Waitzberg DL, Dias MCG, Ozorio GA, coordenadores. Manual de boas práticas em terapia nutricional enteral e parenteral: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP). 3ª ed. Rio de Janeiro: Atheneu; 2022. p. 237-9.
Bruno KA, Silva MJS, Chaves GV. Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma. Acta Oncol. 2021;60(12):1611-20. Doi: https://doi.org/10.1080/0284186X.2021.1983210.
Del Grande M, Rizzo S, Nicolino GM, Colombo I, Rossi L, Manganaro L, et al. Computed tomography–based body composition in patients with ovarian cancer: association with chemotoxicity and prognosis. Front Oncol. 2021;11:718815. Doi: https://doi.org/10.3389/fonc.2021.718815.
Staley SA, Tucker K, Newton M, Ertel M, Oldan J, Doherty I, et al. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecol Oncol. 2020;156(3):695-700. Doi: https://doi.org/10.1016/j.ygyno.2020.01.003.
Zaffina C, Wyttenbach R, Pagnamenta A, Grasso RF, Biroli M, Del Grande F, et al. Body composition assessment: comparison of quantitative values between magnetic resonance imaging and computed tomography. Quant Imaging Med Surg. 2022;12(2):1450. Doi: https://dx.doi.org/10.21037/qims-21-619.
Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004;97(6):2333-8. Doi: https://doi.org/10.1152/japplphysiol.00744.2004.
Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85(1):115-22. Doi: https://doi.org/10.1152/jappl.1998.85.1.115.
Miller RR, Moller NL, Vedal S, Morrison NJ, Staples C. Limitations of computed tomography in the assessment of emphysema. Am Rev Respir Dis. 1989;139(4):980-3. Doi: https://doi.org/10.1164/ajrccm/139.4.980.
Van de Water TA, Lomax AJ, Bijl HP, Schilstra C, Hug EB, Langendijk JA. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):e313-e19. Doi: https://doi.org/10.1016/j.ijrobp.2011.05.005.
Rizzo S, Petrella F, Bardoni C, Bramati L, Cara A, Mohamed S, et al. CT-derived body composition values and complications after pneumonectomy in lung cancer patients: time for a sex-related analysis? Front Oncol. 2022;12:826058. Doi: https://doi.org/10.3389/fonc.2022.826058.
Shachar SS, Deal AM, Weinberg M, Williams GR, Nyrop KA, Popuri K, et al. Body composition as a predictor of toxicity in patients receiving anthracycline and taxane–based chemotherapy for early-stage breast cancer. Clin Cancer Res. 2017;23(14):3537-43. Doi: https://doi.org/10.1158/1078-0432.CCR-16-2266.
Rinninella E, Cintoni M, Raoul P, Ponziani FR, Pompili M, Pozzo C, et al. Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. Intern Emerg Med. 2021;16(5):1341-56. Doi: https://doi.org/10.1007/s11739-020-02589-5.
Santos MAP, Fernandes FCGM, Santos EGO, Souza DLB, Barbosa IR. Tendências de incidência e mortalidade por câncer de ovário nos países da América Latina. Rev Bras Cancerol. 2020;66(4):e06813. Doi: https://doi.org/10.32635/2176-9745.RBC.2020v66n4.813.
Shah R, Polen-De C, McGree M, Fought A, Kumar A. Re-evaluating chemotherapy dosing strategies for ovarian cancer: impact of sarcopenia. Curr Oncol. 2023;30(11):9501-13. Doi: https://doi.org/10.3390/curroncol30110688.
Yoshikawa T, Takano M, Miyamoto M, Yajima I, Shimizu Y, Aizawa Y, et al. Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers. Cancer Chemother Pharmacol. 2017;80(3):555-61. Doi: https://doi.org/10.1007/s00280-017-3395-5.
Copyright (c) 2025 Ciência, Cuidado e Saúde
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
